Who wants to be a billionaire? Not Actelion's founder and CEO, if it means selling out | Fierce Pharma
Clozel's CHF1bn Actelion Spin-Out Idorsia Awaits Janssen Buy-In :: Scrip
Ernst and Young's world Entrepreneur Dr Jean Paul Clozel | Flickr
Actelion CEO Becomes a Billionaire With J&J's Bid for Drugmaker - Bloomberg
Wirtschafts-Deal des Jahres - Der Mann, der es tat – Jean-Paul Clozel verkaufte seine Actelion: «Manchmal packt mich Wehmut»
Actelion spinout Idorsia hits goals in insomnia phase 2, sparking stock rise and talk of partnering up for pivotal trial | Fierce Biotech
How is Actelion Spin-Off Idorsia Doing One Year Later?
J&J seals $30bn Actelion deal in push for rare disease drugs - Gulf Times
Was plant das Ehepaar Clozel? | NZZ
38 Jean Paul Clozel Photos and Premium High Res Pictures - Getty Images
European pharma: CEO talent is the new measure of company calibre
Jean-Paul Clozel
Actelion's Jean-Paul Clozel aims to keep group's independence | Financial Times
Johnson & Johnson Chief Scientific Officer Pharmaceuticals Paul Stoffels (L) and Actelion CEO and founder Jean-Paul Clozel attend a news conference at Actelion headquarters in Allschwil, Switzerland January 26, 2017. REUTERS/Arnd Wiegmann
Actelion in $360M settlement - San Francisco Business Times
Jean-Paul Clozel – mit Herzblut für Actelion - Rendez-vous - SRF
Jean-Paul Clozel - CEO @ Idorsia - Crunchbase Person Profile
Vor der Übernahme ein Rekordergebnis | Tages-Anzeiger
Actelion offers sweetener to stave off attacks - SWI swissinfo.ch
Actelion - Wikipedia
Swiss biotech group Actelion CEO Jean-Paul Clozel arrives for his company's annual general meeting in Basel, May 5, 2011. REUTERS/Christian Hartmann (SWITZERLAND - Tags: BUSINESS HEALTH Stock Photo - Alamy
Actelion Could Boost Takeover Price for Johnson & Johnson
Jean-Paul Clozel | EY - Global
